A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

The global prevalence of MASLD is substantial, with estimates ranging from 30% to 32%, and the incidence of associated conditions like liver ... of fat storage. GLP-1 receptor agonists (GLP ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

Glucagon-like peptide 1 receptor agonists (GLP-1RA) are transforming the treatment of obesity and type 2 diabetes. As an approach to optimize efficacy and minimize side effects, co-agonists ...

Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

Patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) appear to have a very low incidence of nonarteritic anterior ischemic optic neuropathy (NAION) when appropriately ...

GLP-1 receptor agonists emerge as promising therapies for MASLD, addressing metabolic dysfunction and offering potential ...

G-protein coupled receptors regulate hormone secretions in the pancreas. Learn how the complex signaling features ... such as glucagon-like peptide-1, free fatty acids, and catecholamines.

Zepbound (tirzepatide) in an injectable drug that activates receptors in the body for glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptors, researchers said.

Study: Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective. Image Credit: crystal light / Shutterstock ...